Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$4.27
-0.4%
$3.47
$2.01
$5.64
$285.08M1.521.23 million shs264,750 shs
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
$1.60
+0.6%
$1.80
$0.89
$3.19
$47.96M0.12268,282 shs62,024 shs
MediWound Ltd. stock logo
MDWD
MediWound
$20.39
-0.3%
$20.25
$14.14
$22.50
$220.42M0.3271,117 shs8,174 shs
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
$5.12
-3.4%
$4.55
$2.76
$6.00
$241.31M0.4111,341 shs1,761 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
0.00%+5.16%+38.06%+51.77%+90.22%
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
0.00%-8.38%-10.45%-8.91%+30.99%
MediWound Ltd. stock logo
MDWD
MediWound
0.00%+2.15%+7.18%+15.92%+10.00%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
0.00%-0.19%+17.67%+62.85%-2.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
0.9027 of 5 stars
3.40.00.00.00.00.00.6
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
2.3285 of 5 stars
3.63.00.00.02.40.00.6
MediWound Ltd. stock logo
MDWD
MediWound
1.753 of 5 stars
3.51.00.00.01.90.80.6
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
1.9053 of 5 stars
3.35.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2.83
Moderate Buy$11.70174.33% Upside
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
3.17
Buy$8.20414.11% Upside
MediWound Ltd. stock logo
MDWD
MediWound
3.00
Buy$32.2558.17% Upside
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
2.50
Moderate Buy$8.0056.25% Upside

Current Analyst Ratings Breakdown

Latest GANX, NBTX, MDWD, and CRDF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$19.00
7/3/2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/24/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$3.50
6/18/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
6/2/2025
MediWound Ltd. stock logo
MDWD
MediWound
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$34.00
5/22/2025
MediWound Ltd. stock logo
MDWD
MediWound
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$25.00 ➝ $31.00
5/19/2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
5/9/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$17.00 ➝ $18.00
5/2/2025
MediWound Ltd. stock logo
MDWD
MediWound
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$25.00
(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$680K417.28N/AN/A$1.86 per share2.29
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
$50K959.23N/AN/A$0.28 per share5.70
MediWound Ltd. stock logo
MDWD
MediWound
$20.22M10.90N/AN/A$2.89 per share7.06
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
$39.18M6.16N/AN/A($1.51) per share-3.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$45.43M-$0.92N/AN/AN/A-8,308.50%-76.45%-62.85%8/14/2025 (Estimated)
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$20.41M-$0.86N/AN/AN/AN/A-247.55%-146.06%8/6/2025 (Estimated)
MediWound Ltd. stock logo
MDWD
MediWound
-$30.22M-$2.09N/AN/AN/A-110.45%-74.12%-30.92%8/13/2025 (Estimated)
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
-$73.73MN/A0.00N/AN/AN/AN/AN/A9/16/2025 (Estimated)

Latest GANX, NBTX, MDWD, and CRDF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.19N/AN/AN/A$0.10 millionN/A
8/14/2025Q2 2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$0.17N/AN/AN/AN/AN/A
8/13/2025Q2 2025
MediWound Ltd. stock logo
MDWD
MediWound
-$0.55N/AN/AN/A$5.68 millionN/A
5/21/2025Q1 2025
MediWound Ltd. stock logo
MDWD
MediWound
-$0.65-$0.07+$0.58-$0.07$5.20 million$3.96 million
5/14/2025Q1 2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$0.16-$0.16N/A-$0.16$0.03 millionN/A
5/8/2025Q1 2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.19-$0.20-$0.01-$0.20$0.09 million$0.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/AN/AN/AN/AN/A
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
N/AN/AN/AN/AN/A
MediWound Ltd. stock logo
MDWD
MediWound
N/AN/AN/AN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/A
6.22
6.22
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
0.05
2.22
2.22
MediWound Ltd. stock logo
MDWD
MediWound
N/A
2.15
1.99
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/A
1.04
1.04

Institutional Ownership

CompanyInstitutional Ownership
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
16.29%
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
11.97%
MediWound Ltd. stock logo
MDWD
MediWound
46.83%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
38.81%

Insider Ownership

CompanyInsider Ownership
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
7.70%
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
7.18%
MediWound Ltd. stock logo
MDWD
MediWound
9.20%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
3.45%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2066.53 million61.40 millionOptionable
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
2030.07 million27.91 millionOptionable
MediWound Ltd. stock logo
MDWD
MediWound
8010.81 million9.81 millionOptionable
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
10047.13 million45.51 millionNot Optionable

Recent News About These Companies

Nanobiotix price target lowered to $8 from $12 at Guggenheim
Nanobiotix (NBTX) Gets a Hold from UBS
Nanobiotix amends global licensing agreement with Janssen Pharmaceutica

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:CRDF

$4.26 -0.02 (-0.35%)
As of 10:43 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Gain Therapeutics stock logo

Gain Therapeutics NASDAQ:GANX

$1.60 +0.01 (+0.63%)
As of 10:43 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

MediWound stock logo

MediWound NASDAQ:MDWD

$20.39 -0.07 (-0.34%)
As of 10:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Nanobiotix stock logo

Nanobiotix NASDAQ:NBTX

$5.12 -0.18 (-3.40%)
As of 10:41 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.